PANACEA LIFE SCIENCES HOLDINGS, INC.
PLSHOTCHealthcare · Medicinal Chemicals & Botanical Products · NV · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | |
|---|---|---|---|---|---|---|
| Revenue | $2.4M | $1.6M | $2.1M | $836,000 | $215,816 | $0 |
| Operating income | −$5.5M | −$5.7M | −$5.9M | −$2.6M | −$5.7M | −$2.4M |
| Net income | −$8.0M | −$9.1M | −$4.8M | −$2.8M | −$4.5M | −$4.3M |
| Total assets | $18.0M | $19.5M | $23.8M | $6.8M | $9.6M | $14,290 |
| Total liabilities | $26.3M | $21.6M | $16.7M | $5.0M | $2.1M | $3.4M |
| Equity | −$8.3M | −$2.1M | $7.1M | −$3.3M | $4.4M | −$3.4M |
| EPS (diluted) | $-0.48 | $-0.62 | $-0.28 | — | — | — |
| Shares out. | 14.8M | 14.8M | 99.6M | 45.5M | 31.7M | 36.8M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2023- Operating margin
- −232.5%
- Net margin
- −336.1%
- Return on equity
- 96.7%
- Return on assets
- −44.6%
- Return on capital (ROCE)
- —
- Liabilities / assets
- 146.1%
- Debt / equity
- —
- Book value / share
- $-0.56
- Revenue growth (YoY)
- 46.6%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2023- Altman Z″ (distress)
- -13.95distress
- Accruals / assets
- −36.1%clean
- Beneish M-Score
- -4.08normal
- Piotroski F-Score
- 5/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 3 severe● 4 warning● 3 good- Negative shareholder equity
- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- Strong return on equity (>15%)
- Revenue is growing year-over-year
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗Aug 15, 2023
- NT 10-Qmissed a reporting deadline ↗Nov 16, 2021
- NT 10-Qmissed a reporting deadline ↗Aug 17, 2021
- NT 10-Qmissed a reporting deadline ↗May 17, 2021
- NT 10-Kmissed a reporting deadline ↗Mar 30, 2021
- NT 10-Qmissed a reporting deadline ↗Nov 16, 2020
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Buttorff LeslieOfficer — CEO | Sep 18, 2023 | Buy | 20,000 | $0.24 |
| Buttorff LeslieOfficer — CEO | Jun 2, 2023 | Grant | 760,000 | $0.50 |
| Buttorff LeslieOfficer — CEO | May 19, 2023 | Buy | 4,500 | $0.51 |
| Buttorff LeslieOfficer — CEO | May 5, 2023 | Buy | 11,500 | $0.49 |
| Buttorff LeslieOfficer — CEO | Apr 25, 2023 | Buy | 1,000 | $0.32 |
| Buttorff LeslieOfficer — CEO | Apr 3, 2023 | Buy | 1,000 | $0.36 |
| Buttorff LeslieOfficer — CEO | Feb 26, 2023 | Buy | 1,000 | $0.19 |
| Buttorff LeslieOfficer — CEO | Aug 26, 2022 | Buy | 11,500 | $0.14 |
| Wert LawrenceDirector | Aug 11, 2022 | Buy | 5,000 | $0.13 |
| Buttorff LeslieOfficer — CEO | Aug 3, 2022 | Buy | 1,000 | $0.10 |
| Buttorff LeslieOfficer — CEO | Jul 8, 2022 | Buy | 1,600 | $0.20 |
| Buttorff LeslieOfficer — CEO | Apr 4, 2022 | Buy | 11,000 | $0.50 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| Apr 15, 2026 | 12,131 | 1.0 | +100.0% |
| Jan 15, 2026 | 13 | 1.0 | 0.0% |
| Dec 31, 2025 | 13 | 1.0 | +100.0% |
| Oct 31, 2025 | 4,400 | 1.0 | -0.0% |
| Oct 15, 2025 | 4,401 | 1.0 | +100.0% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Entered a material agreement · Other material eventMay 16, 2024
- Changed auditorMay 7, 2024
- Entered a material agreement · New financial obligationMar 7, 2024
- Entered a material agreementFeb 5, 2024
- Entered a material agreement · Completed an acquisition or disposition · Unregistered equity sale · Amended charter or bylaws · Regulation FD disclosureOct 5, 2023
- Entered a material agreement · Other material eventOct 2, 2023
- Entered a material agreement · Regulation FD disclosureJul 10, 2023
- Director / officer changeJun 2, 2023
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.